Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 1 – Immunotherapy of cancer

1523 - Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Date

28 Sep 2019

Session

Poster Discussion 1 – Immunotherapy of cancer

Presenters

Jeroen Creemers

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

J. Creemers1, H. Westdorp2, I. van Oort3, G. Schreibelt1, M. Gorris1, N. Mehra4, M. Simons5, A. de Goede6, M. van Rossum7, S. Croockewit8, C. Figdor1, J..A. Witjes3, E. Aarntzen9, R. Mus9, M. Gotthardt9, J. Barentsz9, J. de Vries2, W.R. Gerritsen10

Author affiliations

  • 1 Tumor Immunology, Radboudumc, 6525GA - Nijmegen/NL
  • 2 Medical Oncology And Tumor Immunology, Radboudumc, 6525 GA - Nijmegen/NL
  • 3 Urology, Radboudumc, Nijmegen/NL
  • 4 Medical Oncology, Radboudumc, 6525 GA - Nijmegen/NL
  • 5 Pathology, Radboudumc, Nijmegen/NL
  • 6 Pharmacy, Radboudumc, 6525 GA - Nijmegen/NL
  • 7 Dermatology, Radboudumc, Nijmegen/NL
  • 8 Hematology, Radboudumc, Nijmegen/NL
  • 9 Radiology And Nuclear Medicine, Radboudumc, 6500 HB - Nijmegen/NL
  • 10 Medical Oncology, Radboudumc, 6500 HB - Nijmegen/NL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1523

Background

Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-derived myeloid and plasmacytoid dendritic cells (mDCs and pDCs).

Methods

In this randomized phase IIa trial, 21 chemo-naive CRPC patients received maximally 9 vaccinations with mature mDCs, pDCs or a combination of mDCs plus pDCs. DCs were stimulated with protamine/mRNA and loaded with tumor-associated antigens NY-ESO-1, MAGE-C2 and MUC1. Primary endpoint was the immunological response after DC vaccination, which was monitored in peripheral blood and in T cell cultures of biopsies of post-treatment delayed-type hypersensitivity (DTH)-skin tests. Main secondary endpoints were safety, feasibility, radiological PFS (rPFS) and OS. Radiological responses were assessed by regular as well as ferumoxtran-10 enriched MRI and 68Ga-PSMA PET/CT scans according to RECIST 1.1, PCWG2 criteria and immune-related response criteria.

Results

Both tetramer/dextramer-positive (dm+) and IFN-γ-producing (IFN-γ+) DTH-skin test-derived antigen specific T cells were present more frequently in patients with radiological non-progressive disease compared to progressive patients (5/13 (38%) vs. 0/8 (0%)). In dm+ and IFN-γ+ patients median rPFS was 18.8 months vs. 5.1 months in patients without IFN-γ+ antigen-specific T cells (p = 0.02). The overall median rPFS was 9.5 months. All DC vaccines were well tolerated with grade 1-2 toxicity. Immunological outcomes and clinical correlates will be presented.

Conclusions

Immunotherapy with primary DC subsets induced functional antigen-specific T cells. The presence of functional antigen-specific T cells correlated with longer rPFS.

Clinical trial identification

NCT02692976.

Editorial acknowledgement

Legal entity responsible for the study

Jolanda de Vries and Winald Gerritsen.

Funding

This work was supported by Stichting Afweer Tegen Kanker, Dr. Paul A.J. Speth Stichting and H2020 EU grant PROCROP (grant No 635122). Carl G. Figdor received ERC Adv Grant PATHFINDER (269019) and the NWO Spinoza grant. I. Jolanda M. de Vries received NWO-Vici grant (918.14.655).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.